The International AIDS Conference is, according to the organizers, the premier gathering for those working in the field of HIV, as well as policy makers, persons living with HIV and other individuals committed to ending the pandemic. It is a chance to assess where we are, evaluate recent scientific developments and lessons learnt, and collectively chart a course forward.
The AIDS 2012 programme is aimed at presenting new scientific knowledge and offer many opportunities for structured dialogue on the major issues facing the global response to HIV. A variety of session types – from abstract-driven presentations to symposia, bridging and plenary sessions – will intend to meet the needs of various participants. Other related activities, including the Global Village, satellite meetings, exhibitions and affiliated independent events, will attempt to contribute to an exceptional opportunity for professional development and networking.
Dr. Javier Martínez-Picado, ICREA Research Professor at the AIDS Research Institute IrsiCaixa, is one of the speakers of the Plenary Sessions on July 24th. The daily Plenary Sessions feature some of the "world’s most distinguished HIV scientists, policy specialists and community leaders". Plenary sessions will bring together all conference delegates at the first session of every morning. The daily plenary topics will set the tone for the week's programme. Dr. Martínez-Picado will be giving a presentation on Viral Eradication – the Cure Agenda, as part of the Challenge and Solutions Plenary Session.
Some other IrsiCaixa reserachers will be attending the International AIDS Conference 2012. See below.
Venue: Walter E. Washington Convention Center (Washington DC USA)
Publications and presentations related to the conference
AIDS Research Institute IrsiCaixa and ICREA, Spain
J. Eron1, D. Cooper2, R. Steigbigel3, B. Clotet4, H. Wan5, J. Zhao5, T. Ly5, D. Hepler5, P. Sklar5, B.-Y. Nguyen5, H. Teppler5, for the BENCHMRK-1 and 2 Study Groups
1University of North Carolina, Chapel Hill, United States, 2University of New South Wales, Sydney, Australia, 3State University of New York, Stonybrook, United States, 4Fundacion Irsicaixa, Barcelona, Spain, 5Merck Sharp & Dohme, Corp., Whitehouse Station, United States
A. Revell1, D. Wang1, F. De Wolf2, J. Gatell3, L. Ruiz4, A. Pozniak5, M.-J. Perez-Elias6, H.C. Lane7, J.S.G. Montaner8, B. Larder1, The Global RDI Study Group
1The HIV Resistance Response Database Initiatve (RDI), London, United Kingdom, 2Netherlands HIV Monitoring Foundation, Amsterdam, Netherlands, 3Hospital Clinic of Barcelona, Barcelona, Spain, 4Fundació irsiCaixa, Badalona, Spain, 5Chelsea and Westminster Hospital, London, United Kingdom, 6Ramón y Cajal Hospital, Madrid, Spain, 7National Institute of Allergy and Infectious Diseases, Bethesda, United States, 8BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
A. Sanvisens1, I. Rivas2, R. Guerola3, P. Cobarsi3, R. Rall4, D. Fuster1, J. Romeu3, B. Clotet5,6, J. Tor1,6, R. Muga1,6
1Hospital Universitari Germans Trias i Pujol, Department of Internal Medicine - HIVACAT, Badalona, Spain, 2Municipal Center for Substance Abuse Treatment, Centro Delta, IMSP, Badalona, Spain, 3Hospital Universitari Germans Trias i Pujol, HIV/AIDS Unit - HIVACAT, Badalona, Spain, 4Centro de Salud Juana Azurduy, Rosario, Argentina, 5Hospital Universitari Germans Trias i Pujol, IrsiCaixa - HIVACAT, Badalona, Spain, 6Universitat Autonoma de Barcelona, Badalona, Spain